As we advance through 2024, artificial intelligence (AI) continues to evolve rapidly, revealing a wealth of transformative possibilities for the pharmaceutical industry. In this article, we examine the top 5 AI predictions for 2024 that are poised to reshape the landscape of drug manufacturing and guide the future of innovation and impact.
Firstly, precision medicine is rising. Gene therapy, a ground-breaking approach, is poised to revolutionize treatment by addressing diseases at the genetic level. Together with genetic testing, gene therapy enables the early detection of diseases and the formulation of personalized treatment plans according to genetic predispositions, paving the way for more accurate and effective healthcare.
Next, there is the integration of Generative AI. This AI subset, which is a part of machine learning, has the unprecedented capacity to autonomously generate innovative content. This can span from drug discovery and development to marketing strategies and patient education resources. Already, 75% of top healthcare firms are experimenting with or intend to expand the use of Generative AI across their enterprises.
Moreover, AI is becoming instrumental in the fight for health equality. Health inequality refers to disparities in access, quality, and outcomes of health services among different populations, often leading to delayed diagnoses or inadequate treatment. Data analytics and AI assist in identifying and prioritizing patients at risk of health disparities, enabling the creation of targeted interventions.
Additionally, remote patient monitoring continues to increase. With the ongoing effects of the pandemic, there is a growing trend towards using mobile applications and specialized devices for patient monitoring. This shift not just facilitates the smooth collection and analysis of patient data, but it also signals a departure from traditional approaches, with technology becoming critical in remolding patient care, clinical research and healthcare delivery.
Lastly, 2024 sees the intensification of privacy regulations and the depreciation of cookies, altering the landscape for targeted patient initiatives. Here, identity resolution is a transformative solution, connecting identifiers across digital touchpoints into a singular consumer identity by merging first-party, second-party, and third-party data. However, it is crucial to have robust privacy, security, and compliance measures in place when working with third-party vendors.
AllazoHealth’s AI platform uses identified patient data securely and in compliance with regulations to ascertain risk factors for every individual patient. The platform is fully HIPAA compliant to ensure maximum patient data protection and uses a secure HIPAA compliant infrastructure based in Azure. In addition, AllazoHealth operates within a SOC-2 compliant environment, with the platform only sending and receiving encrypted data between AllazoHealth and the customers.
To wrap up, the 5 AI predictions for 2024 forecast a future where precision medicine, Generative AI, health equality solutions, remote patient monitoring, and identity resolution all come together to redefine healthcare. AllazoHealth is emerging as the complete AI solution, leading to increased innovation, efficiency, and measurability of success in the pharmaceutical industry’s endeavor to improve patient outcomes through therapy initiation and adherence.
